Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Other Non-Current Assets (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Other Non-Current Assets for 8 consecutive years, with $346111.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 16.8% to $346111.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $346111.0, a 16.8% decrease, with the full-year FY2025 number at $417523.0, changed N/A from a year prior.
  • Other Non-Current Assets was $346111.0 for Q4 2025 at Outlook Therapeutics, down from $417523.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $464388.0 in Q2 2025 to a low of $346111.0 in Q4 2025.